Notice2022-11333
Foreign-Trade Zone (FTZ) 46-Cincinnati, Ohio; Notification of Proposed Production Activity; Patheon Pharmaceuticals Inc. (Pharmaceutical Products), Cincinnati, Ohio
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 26, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 102 (Thursday, May 26, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 102 (Thursday, May 26, 2022)]
[Notices]
[Page 31982]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-11333]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-20-2022]
Foreign-Trade Zone (FTZ) 46--Cincinnati, Ohio; Notification of
Proposed Production Activity; Patheon Pharmaceuticals Inc.
(Pharmaceutical Products), Cincinnati, Ohio
Patheon Pharmaceuticals Inc. (Patheon) submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facilities in Cincinnati, Ohio, within Subzone 46K. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on May 19, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished products include anti-viral tablets
(Nirmatrelvir Active Pharmaceutical Ingredient (API)), anti-viral
tablets (Molnupiravir API), and insomnia treatment tablets (Suvorexant
API) (duty free).
The proposed foreign-status materials and components include:
Lactose monohydrate; colloidal silicon dioxide; magnesium stearate;
sodium stearyl fumarate; Nirmatrelvir API; Molnupiravir API; Suvorexant
API; color film coating formulations containing titanium dioxide (24-
50%); desiccant bag (silica gel); crospovidone; croscarmellose sodium;
microcrystalline cellulose; hydroxypropyl cellulose; tubing (silicone);
pad (polyethylene foam); bags (made of polyethylene); drum (high
density polyethylene); plastic pallets; drum (cardboard); wire seal--
aluminum; plastic coated wire band; and, capsules (vegetable based
vegan capsules) (duty rate ranges from duty-free to 6.5%). The request
indicates that certain materials/components are subject to duties under
Section 301 of the Trade Act of 1974 (Section 301), depending on the
country of origin. The applicable Section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#dbbdafa19bafa9babfbef5bcb4ad"><span class="__cf_email__" data-cfemail="f690828cb68284979293d8919980">[email protected]</span></a>. The closing period for their receipt is July 5, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#17537e76797239517e7961726557636576737239707861"><span class="__cf_email__" data-cfemail="f0b499919e95deb6999e869582b08482919495de979f86">[email protected]</span></a>.
Dated: May 20, 2022.
Elizabeth Whiteman,
Acting Executive Secretary.
[FR Doc. 2022-11333 Filed 5-25-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 26, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.